Hormonal
GLP-1 receptor agonists (GLP-1RA) and dual/triple incretin agonists significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution without worsening fibrosis in patients with MASLD, primarily through indirect mechanisms involving weight loss, improved insulin sensitivity, and reduced hepatic lipogenesis.
If you have fatty liver disease (MASLD/MASH), especially with type 2 diabetes or obesity, GLP-1 based medications (like semaglutide or tirzepatide) are currently the most promising pharmacological treatment. They work by reducing liver fat, inflammation, and improving insulin sensitivity. While they may cause temporary stomach issues, they significantly increase the chance of resolving liver inflammation (MASH). The goal is to stop liver damage progression; fibrosis reversal is still being studied in larger trials. Consult a hepatologist or diabetologist for eligibility.
Incretin analogues appear to be effective treatments for MASH and fibrosis in a large number of clinical trials... Treatment with GLP-1RA limits the harmful effects of lipotoxicity and consequently the progression of MASLD, due to their ability to regulate blood glucose levels and improve insulin sensitivity... GLP-1RA therefore limits hepatic lipogenesis and reduces intrahepatic triglyceride accumulation.
Why this rating
Supported by multiple Phase 2 clinical trials and ongoing Phase 3 trials (ESSENCE), though long-term fibrosis reversal data is still emerging.
Source
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Marwin A. Farrugia et al. · Current Obesity Reports · 2025
DOI 10.1007/s13679-025-00646-8
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →